Opinion: Enough with the me-too drugs. New treatments should be worthy of the people who invest their lives in clinical trials
Drug developers should should treat patients who volunteer for clinical trials the way they would treat their mothers or husbands or best friends — but often don't.
Like many people starting out in the biotech industry, I wanted to make an impact on people’s lives by developing life-changing therapies. But I’ve become disappointed by what I believe are too many companies pushing mediocre and me-too drugs, also known as copycat drugs, into clinical development where they will likely fail.
Clinical trials are more than a way to test new therapies. They offer very sick people hope and a chance for more time with their loved ones. Lately, the drug
